Junko Murai, Shar-yin N Huang, Benu Brata Das, Amelie Renaud, Yiping Zhang, James H Doroshow, Jiuping Ji, Shunichi Takeda, Yves Pommier. Cancer Res 2012
Times Cited: 1099
Times Cited: 1099
Times Cited
Times Co-cited
Similarity
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
39
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
37
PARP inhibitors: Synthetic lethality in the clinic.
Christopher J Lord, Alan Ashworth. Science 2017
Christopher J Lord, Alan Ashworth. Science 2017
28
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Junko Murai, Shar-Yin N Huang, Amèlie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H Doroshow, Yves Pommier. Mol Cancer Ther 2014
Junko Murai, Shar-Yin N Huang, Amèlie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H Doroshow, Yves Pommier. Mol Cancer Ther 2014
25
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling.
Arnab Ray Chaudhuri, André Nussenzweig. Nat Rev Mol Cell Biol 2017
Arnab Ray Chaudhuri, André Nussenzweig. Nat Rev Mol Cell Biol 2017
20
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin,[...]. N Engl J Med 2018
Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin,[...]. N Engl J Med 2018
16
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
16
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia,[...]. Lancet 2017
Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia,[...]. Lancet 2017
14
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu,[...]. N Engl J Med 2015
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu,[...]. N Engl J Med 2015
13
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
13
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action.
Yves Pommier, Mark J O'Connor, Johann de Bono. Sci Transl Med 2016
Yves Pommier, Mark J O'Connor, Johann de Bono. Sci Transl Med 2016
13
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
12
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
12
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J Hall, Joon-Oh Park, Daniel Hochhauser, Dirk Arnold, Do-Youn Oh,[...]. N Engl J Med 2019
Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J Hall, Joon-Oh Park, Daniel Hochhauser, Dirk Arnold, Do-Youn Oh,[...]. N Engl J Med 2019
12
Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Todd A Hopkins, Yan Shi, Luis E Rodriguez, Larry R Solomon, Cherrie K Donawho, Enrico L DiGiammarino, Sanjay C Panchal, Julie L Wilsbacher, Wenqing Gao, Amanda M Olson,[...]. Mol Cancer Res 2015
Todd A Hopkins, Yan Shi, Luis E Rodriguez, Larry R Solomon, Cherrie K Donawho, Enrico L DiGiammarino, Sanjay C Panchal, Julie L Wilsbacher, Wenqing Gao, Amanda M Olson,[...]. Mol Cancer Res 2015
11
Structural basis for allosteric PARP-1 retention on DNA breaks.
Levani Zandarashvili, Marie-France Langelier, Uday Kiran Velagapudi, Mark A Hancock, Jamin D Steffen, Ramya Billur, Zain M Hannan, Andrew J Wicks, Dragomir B Krastev, Stephen J Pettitt,[...]. Science 2020
Levani Zandarashvili, Marie-France Langelier, Uday Kiran Velagapudi, Mark A Hancock, Jamin D Steffen, Ramya Billur, Zain M Hannan, Andrew J Wicks, Dragomir B Krastev, Stephen J Pettitt,[...]. Science 2020
13
The DNA-damage response in human biology and disease.
Stephen P Jackson, Jiri Bartek. Nature 2009
Stephen P Jackson, Jiri Bartek. Nature 2009
11
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer,[...]. N Engl J Med 2019
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer,[...]. N Engl J Med 2019
11
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.
Johann de Bono, Ramesh K Ramanathan, Lida Mina, Rashmi Chugh, John Glaspy, Saeed Rafii, Stan Kaye, Jasgit Sachdev, John Heymach, David C Smith,[...]. Cancer Discov 2017
Johann de Bono, Ramesh K Ramanathan, Lida Mina, Rashmi Chugh, John Glaspy, Saeed Rafii, Stan Kaye, Jasgit Sachdev, John Heymach, David C Smith,[...]. Cancer Discov 2017
10
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Joaquin Mateo, Nuria Porta, Diletta Bianchini, Ursula McGovern, Tony Elliott, Robert Jones, Isabel Syndikus, Christy Ralph, Suneil Jain, Mohini Varughese,[...]. Lancet Oncol 2020
Joaquin Mateo, Nuria Porta, Diletta Bianchini, Ursula McGovern, Tony Elliott, Robert Jones, Isabel Syndikus, Christy Ralph, Suneil Jain, Mohini Varughese,[...]. Lancet Oncol 2020
10
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Robert L Coleman, Gini F Fleming, Mark F Brady, Elizabeth M Swisher, Karina D Steffensen, Michael Friedlander, Aikou Okamoto, Kathleen N Moore, Noa Efrat Ben-Baruch, Theresa L Werner,[...]. N Engl J Med 2019
Robert L Coleman, Gini F Fleming, Mark F Brady, Elizabeth M Swisher, Karina D Steffensen, Michael Friedlander, Aikou Okamoto, Kathleen N Moore, Noa Efrat Ben-Baruch, Theresa L Werner,[...]. N Engl J Med 2019
10
The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication.
Hana Hanzlikova, Ilona Kalasova, Annie A Demin, Lewis E Pennicott, Zuzana Cihlarova, Keith W Caldecott. Mol Cell 2018
Hana Hanzlikova, Ilona Kalasova, Annie A Demin, Lewis E Pennicott, Zuzana Cihlarova, Keith W Caldecott. Mol Cell 2018
10
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow.
Todd A Hopkins, William B Ainsworth, Paul A Ellis, Cherrie K Donawho, Enrico L DiGiammarino, Sanjay C Panchal, Vivek C Abraham, Mikkel A Algire, Yan Shi, Amanda M Olson,[...]. Mol Cancer Res 2019
Todd A Hopkins, William B Ainsworth, Paul A Ellis, Cherrie K Donawho, Enrico L DiGiammarino, Sanjay C Panchal, Vivek C Abraham, Mikkel A Algire, Yan Shi, Amanda M Olson,[...]. Mol Cancer Res 2019
13
The comings and goings of PARP-1 in response to DNA damage.
John M Pascal. DNA Repair (Amst) 2018
John M Pascal. DNA Repair (Amst) 2018
9
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Shiping Jiao, Weiya Xia, Hirohito Yamaguchi, Yongkun Wei, Mei-Kuang Chen, Jung-Mao Hsu, Jennifer L Hsu, Wen-Hsuan Yu, Yi Du, Heng-Huan Lee,[...]. Clin Cancer Res 2017
Shiping Jiao, Weiya Xia, Hirohito Yamaguchi, Yongkun Wei, Mei-Kuang Chen, Jung-Mao Hsu, Jennifer L Hsu, Wen-Hsuan Yu, Yi Du, Heng-Huan Lee,[...]. Clin Cancer Res 2017
9
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää,[...]. N Engl J Med 2019
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää,[...]. N Engl J Med 2019
9
The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.
Thomas Helleday. Mol Oncol 2011
Thomas Helleday. Mol Oncol 2011
9
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
Junko Murai, Ying Feng, Guoying K Yu, Yuanbin Ru, Sai-Wen Tang, Yuqiao Shen, Yves Pommier. Oncotarget 2016
Junko Murai, Ying Feng, Guoying K Yu, Yuanbin Ru, Sai-Wen Tang, Yuqiao Shen, Yves Pommier. Oncotarget 2016
8
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
M E Robson, N Tung, P Conte, S-A Im, E Senkus, B Xu, N Masuda, S Delaloge, W Li, A Armstrong,[...]. Ann Oncol 2019
M E Robson, N Tung, P Conte, S-A Im, E Senkus, B Xu, N Masuda, S Delaloge, W Li, A Armstrong,[...]. Ann Oncol 2019
8
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, William M Sikov, Hope S Rugo, Mark D McKee, Jens Huober, Mehra Golshan, Gunter von Minckwitz, David Maag,[...]. Lancet Oncol 2018
Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, William M Sikov, Hope S Rugo, Mark D McKee, Jens Huober, Mehra Golshan, Gunter von Minckwitz, David Maag,[...]. Lancet Oncol 2018
8
CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.
Michal Zimmermann, Olga Murina, Martin A M Reijns, Angelo Agathanggelou, Rachel Challis, Žygimantė Tarnauskaitė, Morwenna Muir, Adeline Fluteau, Michael Aregger, Andrea McEwan,[...]. Nature 2018
Michal Zimmermann, Olga Murina, Martin A M Reijns, Angelo Agathanggelou, Rachel Challis, Žygimantė Tarnauskaitė, Morwenna Muir, Adeline Fluteau, Michael Aregger, Andrea McEwan,[...]. Nature 2018
8
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.
Geoffrey Kim, Gwynn Ison, Amy E McKee, Hui Zhang, Shenghui Tang, Thomas Gwise, Rajeshwari Sridhara, Eunice Lee, Abraham Tzou, Reena Philip,[...]. Clin Cancer Res 2015
Geoffrey Kim, Gwynn Ison, Amy E McKee, Hui Zhang, Shenghui Tang, Thomas Gwise, Rajeshwari Sridhara, Eunice Lee, Abraham Tzou, Reena Philip,[...]. Clin Cancer Res 2015
8
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.
Constantia Pantelidou, Olmo Sonzogni, Mateus De Oliveria Taveira, Anita K Mehta, Aditi Kothari, Dan Wang, Tanvi Visal, Michelle K Li, Jocelin Pinto, Jessica A Castrillon,[...]. Cancer Discov 2019
Constantia Pantelidou, Olmo Sonzogni, Mateus De Oliveria Taveira, Anita K Mehta, Aditi Kothari, Dan Wang, Tanvi Visal, Michelle K Li, Jocelin Pinto, Jessica A Castrillon,[...]. Cancer Discov 2019
8
Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models.
Hyoung Kim, Erin George, Ryan Ragland, Stavros Rafail, Rugang Zhang, Clemens Krepler, Mark Morgan, Meenhard Herlyn, Eric Brown, Fiona Simpkins. Clin Cancer Res 2017
Hyoung Kim, Erin George, Ryan Ragland, Stavros Rafail, Rugang Zhang, Clemens Krepler, Mark Morgan, Meenhard Herlyn, Eric Brown, Fiona Simpkins. Clin Cancer Res 2017
8
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
8
HPF1 completes the PARP active site for DNA damage-induced ADP-ribosylation.
Marcin J Suskiewicz, Florian Zobel, Tom E H Ogden, Pietro Fontana, Antonio Ariza, Ji-Chun Yang, Kang Zhu, Lily Bracken, William J Hawthorne, Dragana Ahel,[...]. Nature 2020
Marcin J Suskiewicz, Florian Zobel, Tom E H Ogden, Pietro Fontana, Antonio Ariza, Ji-Chun Yang, Kang Zhu, Lily Bracken, William J Hawthorne, Dragana Ahel,[...]. Nature 2020
9
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
8
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs.
Bryan A Gibson, W Lee Kraus. Nat Rev Mol Cell Biol 2012
Bryan A Gibson, W Lee Kraus. Nat Rev Mol Cell Biol 2012
8
PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase.
J C Amé, V Rolli, V Schreiber, C Niedergang, F Apiou, P Decker, S Muller, T Höger, J Ménissier-de Murcia, G de Murcia. J Biol Chem 1999
J C Amé, V Rolli, V Schreiber, C Niedergang, F Apiou, P Decker, S Muller, T Höger, J Ménissier-de Murcia, G de Murcia. J Biol Chem 1999
8
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.
Nuala McCabe, Nicholas C Turner, Christopher J Lord, Katarzyna Kluzek, Aneta Bialkowska, Sally Swift, Sabrina Giavara, Mark J O'Connor, Andrew N Tutt, Małgorzata Z Zdzienicka,[...]. Cancer Res 2006
Nuala McCabe, Nicholas C Turner, Christopher J Lord, Katarzyna Kluzek, Aneta Bialkowska, Sally Swift, Sabrina Giavara, Mark J O'Connor, Andrew N Tutt, Małgorzata Z Zdzienicka,[...]. Cancer Res 2006
7
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
M Catherine Pietanza, Saiama N Waqar, Lee M Krug, Afshin Dowlati, Christine L Hann, Alberto Chiappori, Taofeek K Owonikoko, Kaitlin M Woo, Robert J Cardnell, Junya Fujimoto,[...]. J Clin Oncol 2018
M Catherine Pietanza, Saiama N Waqar, Lee M Krug, Afshin Dowlati, Christine L Hann, Alberto Chiappori, Taofeek K Owonikoko, Kaitlin M Woo, Robert J Cardnell, Junya Fujimoto,[...]. J Clin Oncol 2018
7
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
M William Audeh, James Carmichael, Richard T Penson, Michael Friedlander, Bethan Powell, Katherine M Bell-McGuinn, Clare Scott, Jeffrey N Weitzel, Ana Oaknin, Niklas Loman,[...]. Lancet 2010
M William Audeh, James Carmichael, Richard T Penson, Michael Friedlander, Bethan Powell, Katherine M Bell-McGuinn, Clare Scott, Jeffrey N Weitzel, Ana Oaknin, Niklas Loman,[...]. Lancet 2010
7
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
Benjamin H Lok, Eric E Gardner, Valentina E Schneeberger, Andy Ni, Patrice Desmeules, Natasha Rekhtman, Elisa de Stanchina, Beverly A Teicher, Nadeem Riaz, Simon N Powell,[...]. Clin Cancer Res 2017
Benjamin H Lok, Eric E Gardner, Valentina E Schneeberger, Andy Ni, Patrice Desmeules, Natasha Rekhtman, Elisa de Stanchina, Beverly A Teicher, Nadeem Riaz, Simon N Powell,[...]. Clin Cancer Res 2017
7
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
Jianfeng Shen, Wei Zhao, Zhenlin Ju, Lulu Wang, Yang Peng, Marilyne Labrie, Timothy A Yap, Gordon B Mills, Guang Peng. Cancer Res 2019
Jianfeng Shen, Wei Zhao, Zhenlin Ju, Lulu Wang, Yang Peng, Marilyne Labrie, Timothy A Yap, Gordon B Mills, Guang Peng. Cancer Res 2019
7
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers.
Patrick G Pilié, Carl M Gay, Lauren A Byers, Mark J O'Connor, Timothy A Yap. Clin Cancer Res 2019
Patrick G Pilié, Carl M Gay, Lauren A Byers, Mark J O'Connor, Timothy A Yap. Clin Cancer Res 2019
7
High speed of fork progression induces DNA replication stress and genomic instability.
Apolinar Maya-Mendoza, Pavel Moudry, Joanna Maria Merchut-Maya, MyungHee Lee, Robert Strauss, Jiri Bartek. Nature 2018
Apolinar Maya-Mendoza, Pavel Moudry, Joanna Maria Merchut-Maya, MyungHee Lee, Robert Strauss, Jiri Bartek. Nature 2018
7
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.